Lipoprotein associated phospholipase A2 (Lp-PLA2) is an enzyme with several pro-inflammatory properties that involved in pathogenesis of atherosclerosis but some investigation shows controversial views regarding its biological role. We examined the effect of selective inhibitor of Lp-PLA2 (darapladib) to the inflammation marker such as nuclear factor kappa B (NF-κB) and interleukin-6 (IL-6) expression in aortic tissue and insulin resistance of type 2 diabetes mellitus (T2DM) rat model. 30 sprague dawley rats were randomly divided into normal group, T2DM group and T2DM with darapladib treatment. Induction of T2DM was done by giving high fat diet and low dose injection of streptozotocin. Blood glucose level and insulin plasma concentration were measured to calculate insulin resistance in mice. Eight weeks and sixteen weeks after treatment, we compared expression of NF-κB and IL-6 in aortic tissue. Darapladib treatment group exhibited significant reduction of insulin resistance (0,64+0,11 vs 2,07+0,16, p
Key words: Type 2 Diabetes Mellitus, Inflammation, Insulin Resistance, Lipoprotein-associated phospholipase A2, Darapladib
|
